I n this special article we describe a number of reporting guidelines endorsed by the CONSORT (Consolidated Standards of Reporting Trials) group for a range of research designs that commonly appear in scientific journals: systematic reviews, clinical trials with and without randomisation, observational studies, n-of-1 (or single-case experimental design) trials, and diagnostic studies. We also consider reporting guidelines for studies using qualitative methodology. In addition to reporting guidelines, we present method quality rating scales, which aim to measure risk of bias that threatens the internal validity of a study. Advantages of reporting guidelines and method quality rating scales for authors include the provision of a structure by which to improve the clarity and transparency of report writing; for reviewers and readers advantages include a method by which to critically appraise an article. Brain Impairment endorses these reporting guidelines and applies them within the review process for submissions to the journal.
The standard of scientific writing of reports addressing health conditions has been criticised. As a case in point, Dijkers and colleagues (2002) surveyed papers in six rehabilitation journals representing medicine, nursing, occupational therapy, physiotherapy and psychology over a 2-year period (1997) (1998) . Of the 1,039 peer-reviewed articles published in the journals, there were 646 articles describing original, quantitative research and 171 of the reports described intervention research. These 171 papers reported on 314 interventions using a total of 651 outcome measures. Dijkers et al. highlighted deficiencies in these reports: only 31% of papers reported any type of psychometric information on the outcome measures used and less than 50% of reports described the interventions in sufficient detail to allow replication by an experienced researcher or clinician.
To address the issue of inadequate reporting standards, specific reporting guidelines have been developed for different types of research designs. The purpose of reporting guidelines is a very pragmatic one. They are intended to provide a brief, concise and practical 'user's guide' to publishing reports. The guides include a descriptive checklist which contains a minimum core set of essential items that an author is expected to address when publishing an article. In other words, what needs to be reported and how it should be reported. It is recognised, however, that guidelines have a specific purpose, and in particular, they are not intended to:
• be a 'how to do it' manual (e.g., to stipulate that a specific statistical technique is appropriate for a particular dataset). That level of detail can only be dealt with in specialist articles or textbooks • be evaluative in terms of making recommendations regarding the design and conduct of a study
• provide a measure of the quality of the study (e.g., a method quality scale assessing internal validity) • take the place of a reviewer who will evaluate the study from many perspectives (internal and external validity, clinical relevance, contribution to the literature, etc.).
Nonetheless such reporting guidelines have been demonstrated to be of great value in improving the reporting of health outcome research (Hopewell, Dutton, Yu, Chan, & Altman, 2010) , and they also assist readers, reviewers and journal editors to critically appraise a report. Reporting guidelines generally publish a short article containing the checklist, as well as a more extensive 'elaboration and explanation' paper. The extended document provides rationale for inclusion of the checklist items, along with published extracts of model examples of item reporting. In addition to reporting guidelines, there are also scales available that have a more specific purpose; namely to evaluate method quality of a report. Not all published articles are of equal quality and method quality rating scales provide one way to rate the adequacy of key features of a report. Method quality scales generally focus on risk of bias or threats to the internal validity of a study. A large number of method quality rating scales is available, although it must be said that some authorities have expressed reservations about their use (see Moher et al., 1995; Liberati et al., 2009, for discussion) .
Since its inception, Brain Impairment has published papers with research designs covered by many of these reporting guidelines, including systematic reviews, randomised controlled trials (RCT), non-RCTs, single-participant intervention designs, observational studies (including cohort studies using longitudinal/follow-up designs), studies examining diagnostic tests, and qualitative studies. In the remainder of this editorial, we provide brief description of the pertinent guidelines for the common research designs that appear in Brain Impairment.
Systematic Reviews and the PRISMA Statement
A distinction is often drawn between the traditional narrative review and the systematic review, with the latter commonly regarded as superior (but see Dijkers (2009) for an interesting analysis of this view). As the name suggests, a systematic review aims to systematically and exhaustively examine the literature on a particular topic, using specific methodology (designed to minimise risk of bias), which is fully explicated in the report. Results are synthesised and summarised, thereby making such reviews a valuable source of evidence. When there are sufficient data available, meta-analysis can be used to combine the results of independent studies and conduct quantitative analysis.
The QUOROM (Quality Of Reporting Of Meta-analyses) statement was the original reporting guideline for meta-analyses (Moher et al., 1999) , but not all systematic reviews conduct metaanalysis and the QUOROM statement has now been replaced by the PRISMA (Preferred Reporting Items for Systematic Reviews and Metaanalyses) statement. The statement is provided in Moher et al. (2009) and the explanation and elaboration document in Liberati et al. (2009) . PRISMA is a 27-item checklist (see Table 1 ) that delineates the criteria an author should address 'to ensure clear presentation of what was planned, done, and found in a systematic review' (Liberati et al., p. e2) . The 27 items cover all aspects of the report, including title (1 item), abstract (1 item), introduction (2 items), methods (12 items), results (7 items), discussion (3 items), and funding (1 item).
The PRISMA statement makes reference to the PICOS approach, which is a helpful process to articulate the objectives and research question of a review by formulating pertinent and precise questions regarding the Population of participants with the health condition, Interventions or treatments being evaluated, Comparator or control condition (description of which is generally poor), Outcomes being measured, and Study design.
PRISMA is designed for systematic reviews of RCTs, yet not all treatment studies use randomisation. A reporting guideline specific to systematic review of 'observational' studies, such as those using data from existing databases, cross-sectional study, case series, case-control, cohort and historical controls, is available: Meta-analysis of Observational Studies in Epidemiology (MOOSE; Stroup et al., 2000) .
Although systematic reviews provide Level 1 evidence (see http://www.cebm.net/index.aspx?o= 5653), the adequacy of reporting of systematic reviews is variable. AMSTAR (Assessment of Multiple Systematic Reviews; is an 11-item method quality scale designed for systematic reviews. It was carefully developed and content validity is supported by a statistical item reduction process and expert review. Inter-rater reliability is excellent for the total score (k w = .84, 95% CI: .67-1.00), and moderate to perfect for the individual items (K w = .51-1.00), and the scale also shows evidence of discriminant validity Study selection 9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).
Data collection 10
Describe method of data extraction from reports (e.g., piloted forms, process independently, in duplicate) and any processes for obtaining and confirming data from investigators.
Data items 11
List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.
Risk of bias 12
Describe methods used for assessing risk of bias of individual studies (including in individual specification of whether this was done at the study or outcome level), and how this studies information is to be used in any data synthesis.
Summary measures 13
State the principal summary measures (e.g., risk ratio, difference in means).
Synthesis of results 14
Describe the methods of handling data and combining results of studies, if done, including measures of consistency for each meta-analysis.
Risk of bias 15
Specify any assessment of risk of bias that may affect the cumulative evidence across studies (e.g., publication bias, selective reporting within studies).
Additional 16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, analyses meta-regression), if done, indicating which were pre-specified.
Results

Study selection 17
Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.
Study characteristics 18
For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. . Completion time for the AMSTAR is reported as 15 minutes per report.
Randomised Controlled Trials and the CONSORT Statement
The gold standard methodology for group intervention studies is the randomised controlled trial (RCT), which uses the principles of random and concealed allocation to groups, along with blinding (masking) of those receiving and delivering the intervention/s and assessing the outcomes. Randomisation is important because it allows inferences to be made about cause and effect. It eliminates selection bias and thus balances prognostic variables, both those that are known (e.g., age), as well as those that are unknown (perhaps socioeconomic status or exercise history, or previous therapy are predictors of successful outcome), because participants are assigned to groups by chance. The twin concepts of randomisation consist of (1) random allocation to groups, and (2) concealment of the randomisation schedule from the person who is responsible for recruiting participants, so that they cannot predict which treatment the participant will receive or the group to which the participant will be allocated.
The Consolidated Standards of Reporting Trials (CONSORT) statement is the reporting guideline for RCTs, and the updated version was published in 2010, both for the checklist and the explanation and elaboration document . CONSORT 2010 is a 25-item checklist, although a number of items have multiple components, making 37 items in total (see Table 2 ). Like other statements produced by this research group, items cover all aspects of reporting, including title and abstract (2 items), introduction (2 items), methods (17 items), results (10 items), discussion (3 items), other information (3 items).
A distinctive feature of the CONSORT statement is the flow diagram to facilitate the reporting of the design and conduct of the study, and specifically to describe the flow of participants through different stages of the study. Many RCTs are subject to difficulties with participant flow, in terms of participants not receiving the treatment as allocated, attrition or loss to follow-up, or exclusion from analysis. All these factors can be easily and simply recorded by use of a diagram that is demonstrated in Moher et al. (2010) and reproduced in Figure 1 . [Hopewell et al., 2008] Note: * Reproduced from Schulz et al. (2010) . A number of method quality rating scales of RCTs are available. A widely used scale is the PEDro scale, an 11-item scale that uses 10 items to report a method quality score. The PEDro scale has acceptable inter-rater reliability for the total score for consensus ratings (ICC = .68, 95% CI: .57 to .76) and individual items (k = .50 to.79; Maher, Sherrington, Herbert, Moseley, & Elkins, 2003) .
It is recognised that RCTs are easier to conduct in drug trials than behavioural interventions. Sometimes it is not possible or feasible to conduct either random assignment (e.g., comparing a language therapy to examine its efficacy in anterior versus vs. posterior circulation left hemisphere stroke survivors) and/or blinding (e.g., surgeons need to be aware of the procedure they are performing; similarly therapists need to be aware of the treatment they are delivering). Nevertheless, the elements of randomisation and blinding are considered the most effective ways to minimise the risk of bias and its consequences (e.g., it has been demonstrated that treatment effect is inflated in biased studies; Schulz et al., 1995) . For these reasons, a CONSORT Extension for nonpharmacological studies was developed (Boutron et al., 2008) and is reproduced in Table 3 . A corresponding 10-item method quality scale (CLEAR NPT) is also available (Boutron et al., 2005) , which is reported to take approximately 10 minutes to complete. Parenthetically, the IMPACT group has recognised the particular challenges in conducting clinical trials and observational studies in the area of traumatic brain injury, and the interested reader is referred to their recommendations for the design of studies with this clinical group (Maas et al., 2010) .
Single-Participant Designs and the CENT Statement
One difficulty researchers often encounter with the RCT is that large numbers of participants are generally required to ensure the trial has suffi- 
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How participants were allocated to interventions (e.g., 'random allocation', 'randomised', or 'randomly assigned').
Scientific background and explanation of rationale.
Eligibility criteria for participants and the settings and locations where the data were collected.
Precise details of the interventions intended for each group and how and when they were actually administered.
Specific objectives and hypotheses.
In the abstract, description of the experimental treatment, comparator, care providers, centres, and blinding status.
When applicable, eligibility criteria for centres and those performing the interventions.
Precise details of both the experimental treatment and comparator.
Description of the different components of the interventions and, when applicable, descriptions of the procedure for tailoring the interventions to individual participants.
Details of how the interventions were standardised.
Details of how adherence of care providers with the protocol was assessed or enhanced. Clearly defined primary and secondary outcome measures and, when applicable, any methods used to enhance the quality of measurements (e.g., multiple observations, training of assessors).
How sample size was determined and, when applicable, explanation of any interim analyses and stopping rules.
Method used to generate the random allocation sequence, including details of any restriction (e.g., blocking, stratification).
Method used to implement the random allocation sequence (e.g., numbered containers or central telephone), clarifying whether the sequence was concealed until interventions were assigned.
Who generated the allocation sequence, who enrolled participants, and who assigned participants to their groups.
Whether or not participants, those administering the interventions, and those assessing the outcomes were blinded to group assignment.
Statistical methods used to compare groups for primary outcome(s); methods for additional analyses, such as subgroup analyses and adjusted analyses.
Flow of participants through each stage (a diagram is strongly recommended)-specifically, for each group, report the numbers of participants randomly assigned, receiving intended treatment, completing the study protocol, and analysed for the primary outcome; describe protocol deviations from study as planned, together with reasons.
Dates defining the periods of recruitment and follow-up.
When applicable, details of whether and how the clustering by care providers or centres was addressed.
When applicable, how care providers were allocated to each trial group.
Whether or not those administering co-interventions were blinded to group assignment.
If blinded, method of blinding and description of the similarity of interventions † .
When applicable, details of whether and how the clustering by care providers or centres was addressed. Number of participants (denominator) in each group included in each analysis and whether analysis was by 'intention-to-treat'; state the results in absolute numbers when feasible (e.g., 10/20, not 50%).
For each primary and secondary outcome, a summary of results for each group and the estimated effect size and its precision (e.g., 95% confidence interval).
Address multiplicity by reporting any other analyses performed, including subgroup analyses and adjusted analyses, indicating those prespecified and those exploratory.
All important adverse events or side effects in each intervention group.
Interpretation of the results, taking into account study hypotheses, sources of potential bias or imprecision, and the dangers associated with multiplicity of analyses and outcomes.
Generalisability (external validity) of the trial findings.
General interpretation of the results in the context of current evidence.
When applicable, a description of care providers (case volume, qualification, expertise, and so on) and centres (volume) in each group.
In addition, take into account the choice of the comparator, lack of or partial blinding, and unequal expertise of care providers or centres in each group.
Generalisability (external validity) of the trial findings according to the intervention, comparators, patients, and care providers and centres involved in the trial.
cient power to detect a statistically significant difference. This can be a problem for many conditions with infrequent occurrence, and health conditions occurring with acquired brain impairment are one such area -it is unlikely that there will ever be an RCT to determine the effect of an intervention for prosopagnosia! There are also other limitations in the clinical application of results from RCTs, which have been described by many authorities (see Guyatt et al., 1986; Wilson, 1987) . One research design that can overcome these problems is the n-of-1 trial (also known as the single-case experimental design, SCED). Traditionally, in mainstream medicine, these single-participant designs have either been ignored or (erroneously) dismissed as providing an inferior level of evidence. Due to the efforts of a number of research teams, however, this state of affairs has been rectified. The Oxford Centre for Evidence-Based Medicine, one of the peak bodies in the field, has revised their levels of evidence and now the n-of-1 trial is introduced as Level 1 evidence for patient treatment decisions, on equal footing with the systematic review of multiple RCTs; a single RCT is classified as Level 2 evidence (Howick et al., 2011) .
It needs to be emphasised that the n-of-1 trial and single-case experimental design should not be confused with a simple case report or description; rather, as we have written elsewhere, they 'differ radically from anecdotal, uncontrolled case descriptions. They represent the intensive and prospective study of the individual, using an a priori methodology, which includes systematic observation, manipulation of variables, repeated measurement and data analysis.' (Tate et al., 2008, p. 3) . Not only does the single case experimental design (SCED) have methodological rigour, but there is also a range of statistical techniques designed specifically for the them (see Kazdin, 2011; Perdices & Tate, 2009 ).
An international research team, led by the University of Alberta, Canada, is currently developing reporting guidelines for n-of-1 trials, which will be known as the CONSORT Extension for N-of-1 Trials (CENT) statement (personal communication, S Vohra, March 11, 2011). A complementary team, led by the University of Sydney, Australia, is currently working on a similar guideline for behavioural intervention studies with single-participant designs. When published, the CENT statement will join the statements recommended by Brain Impairment.
To our knowledge, there is only a single method quality scale with demonstrated psychometric properties that has been published. The SCED Scale is an 11-item scale, which uses 10 items to provide a method quality score. The SCED Scale has good inter-rater reliability for the total score for consensus ratings (ICC = .88, 95% CI: .78 to .95) and fair-to-perfect reliability for individual items (k = .48 to 1.0; Tate et al., 2008) . Administration time is generally 15 to 20 minutes. The SCED Scale has undergone minor revision including addition of a new item, and version 2 will be available shortly.
Observational Studies and the STROBE Statement
Most reporting guidelines focus on a single methodological design. The statement on Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) is special in that it addresses multiple designs. The STROBE statement is reported in von and the explanation and elaboration document in Vandenbroucke et al. (2007) . Three types of designs addressed by STROBE are cohort studies (using follow-up or longitudinal methods), casecontrol designs (e.g., for studies examining risk factors), and cross-sectional research (addressing incidence/prevalence issues). Although STROBE was not developed for case reports or case series, Vandenbroucke and colleagues note the applicability of a number of STROBE items to such designs. They suggest that authors/reviewers of case reports and case series may find the statement helpful.
The STROBE statement contains a 22-item checklist (see Table 4 ) addressing title and abstract (1 item), introduction (2 items), methods (9 items), results (5 items), discussion (4 items), and other information (1 item). The combined checklist addressing all three designs is presented in Table 4 , but separate checklists for each of the designs are available from the STROBE website (http://www.strobe-statement.org).
A method quality rating scale suitable for observational studies (specifically cohort and casecontrol), as well as randomised trials, was developed by Downs and Black (1998) . This method rating scale has a broad base in that it addresses external validity (specifically generalisation) as well as internal validity. The scale contains 26 items in four subscales: Reporting (10 items), Confounding (6 items), Bias (7 items) and External validity (3 items). Inter-rater reliability is moderate for the total score (r = .75), but that for the subscales ranges from good (Bias r = .83) to poor (External validity r = -.14). Administration time averages 20 to 25 minutes (range 10-45 mins).
Diagnostic Test Accuracy and the STARD Statement
The Standards for Reporting of Diagnostic Accuracy (STARD) initiative grew from concerns expressed by the Cochrane Diagnostic and Screening Test Methods Working Group at the Rome Cochrane Colloquium meeting in 1999. During this meeting the Working Group discussed the poor methodological and reporting quality of studies evaluating diagnostic tests and highlighted the importance of rigorous determination of the diagnostic accuracy of tests in the context of patient care. In line with the CONSORT process, the Working Group developed a checklist of items required in a report of a study of diagnostic accuracy. The resultant STARD statement (Bossuyt et al., 2003a) and its accompanying explanation and elaboration statement (Bossuyt et al., 2003b) were published simultaneously in several medical journals. Studies of diagnostic accuracy require that the outcomes of a test for a target health condition are evaluated by comparison with the outcomes of an established reference standard for that health condition. Within the STARD statement, the term test is broadly defined and refers to any method of obtaining data about an individual's health condition: 'It includes information from history and physical examination, laboratory tests, imaging tests, function tests and histopathology' (Bossuyt et al., 2003a, pp. 1-2) . The term 'health condition' covers any identifiable target condition that triggers a clinical action (e.g., further assessment, initiation or termination of intervention), the reference standard is the best available test/s or method/s for establishing the presence or absence of the particular health condition, and the test being evaluated is termed the 'index test'. In the context of this framework, accuracy refers to the degree of agreement between the information from the index test and the reference standard in the target condition. Various diagnostic efficiency statistics (e.g., sensitivity and specificity, the odds ratio, the likelihood ratio, the area under receiver operator characteristic (ROC) curve, positive and negative predictive power, kappa and phi) can be applied in the evaluation of diagnostic accuracy. Streiner (2003) and Deeks (2001) provide useful reference summaries of diagnostic efficiency statistics.
The 25-item checklist developed as a result of the STARD initiative covers all aspects of reporting, including title, abstract and keywords (1 item), introduction (1 item), methods (11 items), results Generalisability 21 Discuss the generalisability (external validity) of the study results.
Other information Funding 22
Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based.
Note: * Reproduced from von (11 items), and discussion (1 item). A prototypical flowchart was also developed to present detailed information about the method of patient recruitment, the order of test execution and the number of patients present and classified at each stage of a diagnostic accuracy study. The documents are freely available without copyright restrictions and can be downloaded from the STARD website at http://www.stard-statement.org/. The checklist is reproduced in Table 5 and the flow diagram is reproduced in Figure 2 . Smidt et al. (2006) investigated inter-assessment, and intra-and inter-observer reproducibility of the STARD checklist. The overall reproducibility of the quality of reporting on diagnostic studies using the STARD items was high (inter-assessment agreement 85%) and the inter-assessment reliability was acceptable (intercorrelation coefficient, ICC = 0.79; 95% CI: 0.62 to 0.89). However, substantial disagreements were found on specific individual items. Smidt et al. concluded that these disagreements reflected difficulties evaluating the specific items due to poor reporting within the articles rather than differences in interpretation of the items by the reviewers. It should be emphasised that the content of the STARD checklist and flowchart is relevant to most studies examining the validity of The study population: The inclusion and exclusion criteria, setting and locations where the data were collected.
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Participant recruitment: Was recruitment based on presenting symptoms, results from previous tests, or the fact that the participants had received the index tests or the reference standard.
5
Participant sampling: Was the study population a consecutive series of participants defined by the selection criteria in items 3 and 4? If not specify how the participants were further selected.
6
Data collection: Was data collection planned before the index test and reference standard were performed (prospective study) or after (retrospective study)?
Test methods 7 The reference standard and its rationale.
8
Technical specifications of material and methods involved including how and when measurements were taken, and/or cite references for index tests and reference standard.
9 Definition of and rationale for the units, cutoffs and/or categories of the results of the index tests and the reference standard.
10
The number training and expertise of the persons executing and reading the index tests and the reference standard.
11
Whether or not the readers of the index test and reference standard were blind (masked) to the results of the other test and describe any other clinical information available to the readers.
Statistical methods 12
Methods for calculating or comparing diagnostic accuracy, and the statistical methods used to quantify uncertainty (e.g., 95% confidence intervals).
13
Methods for calculating test reproducibility, if done.
Results
Participants 14
When study was done, including beginning and ending dates of recruitment.
15
Clinical and demographic characteristics of the study population (e.g., age, sex, spectrum of presenting symptoms, comorbidity, current treatments, recruitment centres).
assessment instruments. Thus, the information can be applied to guide the preparation and review of any report concerning the development of an assessment instrument. Assessment of method quality in systematic reviews of diagnostic accuracy studies is just as essential as it is in any other systematic review. Given the unique design features and efficiency statistics associated with diagnostic accuracy studies, it follows that a tool specific to diagnostic accuracy studies is required to evaluate the methodological quality of such studies. Numerous checklists for assessment of diagnostic accuracy studies have appeared in the literature over the years. However, the QUADAS (Quality Assessment of Diagnostic Accuracy Studies) is the only one that has been developed systematically (Whiting, Rutjes, Reitsma, Bossuyt, & Kleijnen, 2003) and evaluated (Whiting et al., 2006) . This tool defines quality in terms of both internal and external validity of a study. It was developed based upon reviews of empirical evidence and a formal consensus procedure with a panel of experts in diagnostic research. The QUADAS checklist contains 14 items covering bias (9 items), variability (2 items) and reporting (3 items). An 11-item version of the tool is recommended for quality assessment of studies in Cochrane Systematic Reviews of Diagnostic Accuracy (Reitsma et al., 2009 ). This 11-item Cochrane version of the checklist does not include the 3 items related to reporting in the original publication of the tool (Whiting et al., 2003) .
Evaluation of the QUADAS revealed good agreement between reviewers and the final consensus ratings (85% to 91%; Whiting et al., 2006 ). At the individual item level, two items (item 13: uninterpretable results; item 14: withdrawals) were problematic and the guidelines for scoring these items were modified. QUADAS was found to be relatively quick to complete taking less than 30 minutes by 85% of reviewers. More recently, Mann, Hewitt and Gilbody (2009) examined the utility of QUADAS when assessing diagnostic accuracy studies using psychometric instruments in the clinical context of postnatal depression. The results were broadly congruent with those of the original evaluation (Whiting et al., 2006) with good overall level of agreement (85.7%) and good agreement (> 80%) on the majority of items. 
FIGURE 2
Prototypical flow diagram of a diagnostic accuracy study.
Source:http://www.stard-statement.org/
Qualitative Studies and Reporting Guidelines
Qualitative research can be defined broadly as naturalistic, social inquiry that focuses on understanding the way people interpret their experiences and their world (Denzin & Lincoln, 1994; Malterud, 2001) . Qualitative research has not emerged from a single tradition. Consequently, there are multiple approaches to qualitative research reflecting diverse philosophies. In the context of the healthcare literature, the most frequently encountered approaches are ethnography, grounded theory, phenomenology, case study and action research (Cohen & Crabtree, 2006) . analysis, thematic analysis and the constant comparative method of grounded theory.
Opinions regarding the utility of having a set or checklist of criteria for assessing qualitative research are not unified and several perspectives have been expressed in the literature. These perspectives range from the belief that the breadth and diversity of qualitative research prohibits the development of a single set of criteria to the belief that a set of well-defined, appropriate standards and criteria is needed to avoid the risk of quantitative standards and criteria being applied erroneously to qualitative research (See Cohen and Crabtree, 2008 for a discussion of this issue). Nevertheless, there are several sources of guidance for reporting qualitative research. Some of these guidelines have been developed to apply to specific data collection methods (e.g., COREQ a reporting checklist for in-depth interviews and focus groups developed by Tong, Sainsbury & Craig, 2007) , while others have been developed to be inclusive of work emerging from the broad diversity of qualitative traditions. Two sets of guidelines developed to support authors and reviewers across the range of qualitative studies are summarised in Table 6 . Both these sets of guidelines provide excellent guidance for authors and reviewers across four broad areas: (1) relevance of the study question, (2) appropriateness of the qualitative approach, (3) rigour of data collection and sampling procedures, and (4) interpretation and discussion. The first set was developed by Malterud (2001) and includes 30 items to guide the review of all aspects of manuscripts reporting qualitative studies: aim (3 items), reflexivity (1 item), method and design (2 items), data collection and sampling (5 items), theoretical framework (3 items), analysis (4 items), findings (4 items), discussion (5 items), presentation (2 items), and references (1 item). This guideline can be found in the original publication (Malterud, 2001, p. 485) and is reproduced on the Qualitative Research Guidelines Project website: http://www. qualres.org/index.html.
The second qualitative research reporting guideline was developed by Clark (2003) and is referred to by the acronym RATS, derived from the broad domains covered by the guideline: Relevance of study question, Appropriateness of qualitative method, Transparency of procedures, and Soundness of interpretive approach. Clark's guidelines with minor modifications are available through the EQUATOR (Enhancing the Quality and transparency of health research) network library for health research reporting: http://www. equator-network.org/. This guideline lists 22 items across core areas that are expected to be covered in a qualitative report: relevance of study question (2 items), appropriateness of qualitative method (1 item), sampling (2 items), recruitment (2 items), data collection (3 items), role of researchers (1 item), ethics (3 items), analysis (4 items), and discussion and presentation (4 items). Additional information specific to the methodological diversity within qualitative research is provided in the method (item 3), sampling (item 5), and analysis (item 15) areas. This additional information can be particularly useful for the less experienced author or reviewer of qualitative reports.
Assessment of method quality in qualitative research has given rise to substantial discussion in the literature over the past decade (e.g., Cohen & Crabtree, 2008; Dixon-Woods et al., 2007; Mays & Pope, 2000; Noyes, Popay, Pearson, Hannes, & Booth, 2011; Walsh & Downe, 2006) and numerous instruments have been developed to support quality appraisal of qualitative research (Noyes et al. 2011 ). Spencer, Ritchie, Lewis, and Dillon (2003) developed a framework of quality criteria based on comprehensive review of qualitative methodological literature and existing guidelines as well as expert consensus. Cognisant of the broad church of qualitative research, these authors adopted an 'elemental' approach to quality appraisal whereby the premises underpinning social enquiry informed the criteria covered by the framework. Consequently, this framework is relevant for a range of qualitative methods. The framework consists of 18 appraisal questions covering findings (5 questions), design (1 question), sample (2 questions), data collection (1 question), analysis (4 questions), reporting (2 questions), reflexivity and neutrality (1 question), ethics (1 question), and auditability (1 question). Each question is accompanied by a set of quality indicators to guide the appraisal. This framework can be downloaded from the United Kingdom Government Social Research Service website: http://www.civilservice.gov.uk/Assets/a_quality_f ramework_tcm6-7314.pdf
Critical appraisal checklists for qualitative research have also been incorporated into software developed by evidence synthesis organisations. For example, the JBI-QARI (Qualitative Assessment and Review Instrument) was prepared for the Joanna Briggs Institute (JBI: http://www.jbiconnect.org). JBI-QARI is a webbased database that incorporates a critical appraisal scale, data extraction forms, and a data synthesis function (Pearson, 2003) . It facilitates the inclusion of the findings of qualitative research studies as part of a systematic review of evidence. and compared with other options.
• Theoretical: based on preconceived or 11 Characteristics of the sample presented in emergent theory sufficient detail to understand the site and
• Purposive: diversity of opinion context of the study.
• Volunteer: feasibility, hard-to-reach groups Recruitment 6 Recruitment conducted using appropriate methods. for during analysis.
• Thematic: exploratory, descriptive, Analysis 15 Principles and procedures for data organisation hypothesis generating and analysis are fully described.
• Constant comparison/grounded theory:
16 How categories were identified is stated clearly theory generating, analytical.
(from theories or preconception in advance or
16
Interpretations are presented clearly and developed from the data).
supported adequately by the evidence. theoretical and empirical references.
22
The manuscript is well-written and accessible.
27 Clear consequences of the study are proposed.
Presentation 28 The report is easy to understand and clearly contextualised.
29 The voices of the informants and the researcher are distinguishable.
The JBI-QARI critical appraisal instrument consists of 10 items focusing on 3 areas: philosophical and methodological congruity (5 items), explication of researcher biases (2 items), and representation of the participants' perspectives and their relationship to the conclusions (3 items). Current opinion regarding the value of and need for formal quality appraisal tools in relation to qualitative research continues to be divided. However, there is little doubt that evidence from qualitative studies can make an important contribution to systematic reviews across healthcare practice. Further, few would take exception to the need to establish the quality of evidence before using it to inform clinical practice. Thus, it is not surprising that methods to assist the critical appraisal of qualitative studies continue to appear in the literature. The reader who is interested in following developments in this area is referred to the Cochrane Qualitative Research Methods Group (QRMG): www.joannabriggs.edu.au/cqrmg.
Concluding Remarks
The reporting guidelines described in the foregoing are those that commonly relate to papers published in Brain Impairment, and Brain Impairment endorses these reporting guidelines. Reviewers and editors will use these standards when assessing submissions to the journal and authors are strongly encouraged to adhere to the the items of the relevant reporting guideline when preparing a manuscript.
Although reporting of ethical approval to conduct a study is not included in all these checklists, it is recognised that ethics approval is generally necessary to conduct research on human participants (as well as animals) and Brain Impairment requires that authors include a statement about ethics approval to conduct their study.
As editors, we agree with the position of the developers of STROBE: by using the above reporting guidelines for articles submitted to Brain Impairment we do not suggest that the guideline structure needs to be followed 'in a rigid format. The checklist items should be addressed in sufficient detail and with clarity somewhere in an article, but the order and format for presenting information depends on author preferences, journal style, and the traditions of the research field ' (von Elm et al., , pp. 1455 ' (von Elm et al., -1456 .
Reporting guidelines are recognised by their developers to be evolving documents, and they require revisions and refinement in the light of new information. There are many other reporting guidelines in addition to those described in this special editorial and the interested reader is referred to EQUATOR Network (http://www.equator-network.org/resource centre/library-of-health-researchreporting/), established in 2008, which is a useful resource including a library of reporting guidelines.
